由我們的結果發現 IL-1β、IL-6 以及 TGF-β 於腫瘤細胞的表現分別與其在基質及 浸潤之免疫細胞表現呈正相關。這顯示腫瘤細胞中這些細胞激素的表現越高，也能增 加基質以及浸潤之免疫細胞的表現，兩者之間是呈正向的回饋。此外，IL-1β 與 IL-6
的表現呈現正相關，且其於組織切片上的表現型態相同，顯示OSCC 中 IL-1β 應該有
向上調控IL-6 的能力。IL-6 以及 IL-1β 的表現與 TGF-β 也呈現正相關，或許是為了拮 抗IL-1β 以及 IL-6 啟動的免疫反應而產生。IL-1β 在 T3 及 T4 的腫瘤以及第三期與第
四期的腫瘤中表現量較高，顯示較具侵犯性的 OSCC 中 IL-1β 的表現是比較高的。
Foxp3 的表現則與 IL-1β 相反，於 T1 以及 T2 與第一期以及第二期的腫瘤中表現較高，
顯示在較早期、較不具侵犯性的 OSCC 中 Treg 的表現會較高。有喝酒習慣的患者，
腫瘤基質中IL-6 的表現會比較高。有抽菸習慣的患者，IL-1β 於腫瘤細胞中的表現會
比較高。而Foxp3 的表現則是在不嚼食檳榔的患者表現較高。三者的結果都顯示了會
促進組織的發炎反應，顯示OSCC 與發炎之間有很密切的關係。TGF-β 於腫瘤細胞表
現較高的患者累積存活率較高，顯示TGF-β 的表現有助於 OSCC 的預後。TGF-β 在分 化較好的腫瘤組織中的表現會較分化較差的腫瘤組織來的高，而從染色切片的觀察，
TGF-β 主要也表現於分化較好的腫瘤細胞中。但在本研究中，Treg、IL-1β 以及 IL-6 對於患者之累積存活率並沒有影響。其他如患者年紀、性別，腫瘤的位置、淋巴結的
轉移、淋巴或血管的侵犯、轉移淋巴結之膜外擴散以及腫瘤復發，皆與Foxp3、IL-1β、
IL-6 以及 Foxp3 於 OSCC 中的表現無關。
37
附表與附圖
表1
IL-1β、IL-6 及 TGF-β 於 OSCC 腫瘤細胞上之陽性染色之標記指數(Labeling Index)、
強度(Intensity)及平均標記分數(Labeling score)
Cell type Labeling Index for Positive Cells Intensity Scores Mean Labeling Score 0 1 2 3 4 0 1 2 3
IL-1β 1 16 17 16 21 1 23 24 23 5.6 ± 3.9
IL-6 0 15 13 8 35 0 25 29 17 5.9 ± 3.9
TGF-β 1 4 7 29 30 1 20 27 23 6.8 ± 3.7
Labeling index: 0(no staining), 1(0-10% positive cells), 2(10-50% positive cells), 3(50-80%
positive cells), 4(80-100% positive cells);
Intensity score: 0(no staining), 1(mild), 2(moderate), 3(Strong)
所有病例皆表現IL-6 及 Foxp3 陽性染色，而 IL-β 及 TGF-β 各有一病例未呈現陽性染 色。
38
表2
IL-1β、IL-6 及 TGF-β 於 OSCC 基質細胞及浸潤之免疫細胞上陽性染色之標記指數 (Labeling Index)
Cell type Labeling Index for Positive Cells 0 1 2 3 4
IL-1β 5 8 14 15 29
IL-6 0 13 19 20 19
TGF-β 1 3 21 25 21
所有病例之基質細胞及浸潤之免疫細胞皆表現IL-6陽性染色，IL-1β有5例未表現，
TGF-β則有1例未表現。Foxp3於腫瘤浸潤的免疫細胞中表現的平均標記指數為 6.3±4.0(%)，範圍為2-15%之間。
39
LI= labeling index; CLI= cancer cell labeling index; IS= intensity score; CLS= cancer labeling score; SILI= stromal and infiltrating immune cell labeling index.
40
表4
年齡與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數之相關 性
Age < 50
(n= 30) (Mean ± SD)
Age ≧ 50
(n= 41) p-Value
IL-1β CLI 2.5 ± 1.1 2.6 ± 1.2 0.856
IL-1β IS 2.0 ± 0.9 1.9 ± 0.8 0.422
IL-1β CLS 5.8 ± 3.9 5.5 ± 4.0 0.744 IL-1β SILI 2.5 ± 1.4 3.0 ± 1.2 0.126
IL-6 CLI 2.8 ± 1.3 3.0 ± 1.2 0.614
IL-6 IS 2.0 ± 0.8 1.8 ± 0.7 0.292
IL-6 CLS 6.1 ± 4.1 5.9 ± 3.9 0.770
IL-6 SILI 2.5 ± 1.1 2.7 ± 1.1 0.503 TGF-β CLI 3.0 ± 1.1 3.3 ± 0.8 0.190
TGF-β IS 1.9 ± 0.9 2.1 ± 0.7 0.319
TGF-β CLS 6.4 ± 4.1 7.1 ± 3.4 0.419 TGF-β SILI 2.9 ± 1.1 2.9 ± 0.8 0.960
Foxp3 LI 5.3 ± 3.8 7.0 ± 4.0 0.067
41
表5
性別與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數之相關 性
Female (n= 6)
(Mean ± SD)
Male
(n= 65) p-Value
IL-1β CLI 2.0 ± 1.3 2.6 ± 1.2 0.216
IL-1β IS 1.6 ± 0.8 2.0 ± 0.8 0.336
IL-1β CLS 3.3 ± 2.6 5.8 ± 4.0 0.144 IL-1β SILI 2.3 ± 1.4 2.8 ± 1.3 0.330
IL-6 CLI 2.7 ± 1.2 2.9 ± 1.2 0.601
IL-6 IS 1.5 ± 0.5 1.9 ± 0.7 0.208
IL-6 CLS 4.2 ± 2.6 6.1 ± 4.0 0.303
IL-6 SILI 1.8 ± 0.8 2.7 ± 1.1 0.053 TGF-β CLI 3.0 ± 1.1 3.2 ± 0.9 0.679
TGF-β IS 2.0 ± 0.9 2.0 ± 0.8 0.948
TGF-β CLS 6.5 ± 4.0 6.9 ± 3.7 0.851 TGF-β SILI 2.5 ± 1.2 2.9 ± 0.9 0.317
Foxp3 LI 8.5 ± 4.3 6.1 ± 4.0 0.123
42
表6
腫瘤位置與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數之 相關性
Cheek (n= 34)
(Mean ± SD)
Tongue (n= 28)
Gingiva and palate (n= 9)
p-Value
IL-1β CLI 2.4 ± 1.2 2.6 ± 1.2 2.8 ± 1.2 0.736 IL-1β IS 2.0 ± 0.8 1.9 ± 0.9 2.0 ± 0.9 0.965 IL-1β CLS 5.6 ± 4.0 5.5 ± 3.9 6.1 ± 4.2 0.919 IL-1β SILI 2.9 ± 1.3 2.6 ± 1.3 3.0 ± 1.3 0.546 IL-6 CLI 2.8 ± 1.3 2.9 ± 1.2 3.2 ± 1.3 0.580 IL-6 IS 2.0 ± 0.8 1.9 ± 0.7 1.8 ± 0.8 0.833 IL-6 CLS 6.0 ± 4.1 5.9 ± 3.7 6.3 ± 4.3 0.966 IL-6 SILI 2.6 ± 1.1 2.5 ± 1.1 3.0 ± 1.1 0.511 TGF-β CLI 3.3 ± 0.9 3.0 ± 0.9 3.2 ± 0.8 0.335 TGF-β IS 2.0 ± 0.9 2.0 ± 0.7 2.3 ± 0.7 0.461 TGF-β CLS 7.0 ± 4.0 6.2 ± 3.5 7.8 ± 3.3 0.467 TGF-β SILI 2.7 ± 1.0 2.9 ± 0.9 3.3 ± 0.7 0.211 Foxp3 LI 6.6 ± 4.2 6.1 ± 4.0 5.6 ± 3.2 0.861
43
表7
腫瘤大小(T)與 IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數 之相關性
T1 + T2
(n= 40) (Mean ± SD)
T3 + T4
(n= 31) p-Value
IL-1β CLI 2.3 ± 1.1 3.0 ± 1.1 0.010*
IL-1β IS 1.8 ± 0.8 2.3 ± 0.8 0.011*
IL-1β CLS 4.4 ± 3.4 7.2 ± 4.0 0.002*
IL-1β SILI 2.6 ± 1.4 3.0 ± 1.1 0.197
IL-6 CLI 2.8 ± 1.2 3.0 ± 1.3 0.633
IL-6 IS 1.9 ± 0.8 1.9 ± 0.8 0.879
IL-6 CLS 5.7 ± 3.8 6.3 ± 4.2 0.552
IL-6 SILI 2.6 ± 1.1 2.7 ± 1.1 0.765 TGF-β CLI 3.3 ± 0.8 3.0 ± 1.1 0.276
TGF-β IS 2.1 ± 0.8 1.9 ± 0.8 0.197
TGF-β CLS 7.3 ± 3.7 6.2 ± 3.7 0.212 TGF-β SILI 2.7 ± 0.9 3.0 ± 0.9 0.132 Foxp3 LI 7.4 ± 4.0 4.9 ± 3.5 0.006*
44
表8-1
淋巴結轉移(N)與 IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分 數之相關性
N0 (n= 46)
(Mean ± SD)
N1 (n= 8)
N2
(n= 17) p-Value
IL-1β CLI 2.4 ± 1.1 2.1 ± 1.6 3.1 ± 1.1 0.069 IL-1β IS 1.9 ± 0.8 1.9 ± 0.8 2.1 ± 0.8 0.524 IL-1β CLS 5.2 ± 3.8 4.5 ± 4.2 7.2 ± 3.9 0.130 IL-1β SILI 2.8 ± 1.3 2.3 ± 1.5 3.0 ± 1.0 0.387 IL-6 CLI 2.8 ± 1.3 2.6 ± 1.2 3.3 ± 1.1 0.255 IL-6 IS 1.8 ± 0.8 2.0 ± 0.5 2.1 ± 0.7 0.413 IL-6 CLS 5.7 ± 4.1 5.3 ± 2.4 7.1 ± 3.9 0.334 IL-6 SILI 2.6 ± 1.1 2.1 ± 1.1 2.9 ± 1.1 0.268 TGF-β CLI 3.3 ± 0.9 3.1 ± 1.0 2.9 ± 1.0 0.426 TGF-β IS 2.0 ± 0.8 2.5 ± 0.5 1.7 ± 0.9 0.086 TGF-β CLS 7.0 ± 3.6 8.0 ± 3.3 5.7 ± 3.9 0.264 TGF-β SILI 3.0 ± 0.8 2.6 ± 1.3 2.8 ± 1.0 0.742 Foxp3 LI 6.2 ± 4.1 7.8 ± 3.7 5.8 ± 3.9 0.355
45
表8-2
淋巴結轉移(N)與 IL-1β、IL-6、TGF-β與 Foxp 各項陽性染色標記指數、強度、標記 分數之相關性
N0 (n= 46)
(Mean ± SD)
N1 + N2
(n= 25) p-Value
IL-1β CLI 2.4 ± 1.1 2.8 ± 1.3 0.205 IL-1β IS 1.9 ± 0.8 2.1 ± 0.9 0.449 IL-1β CLS 5.2 ± 3.8 6.4 ± 4.1 0.328 IL-1β SILI 2.8 ± 1.3 2.8 ± 1.2 0.965 IL-6 CLI 2.8 ± 1.3 3.1 ± 1.2 0.418 IL-6 IS 1.8 ± 0.8 2.0 ± 0.7 0.185 IL-6 CLS 5.7 ± 4.1 6.6 ± 3.5 0.276 IL-6 SILI 2.6 ± 1.1 2.6 ± 1.1 0.955 TGF-β CLI 3.3 ± 0.9 3.0 ± 1.0 0.229 TGF-β IS 2.0 ± 0.8 2.0 ± 0.9 0.764 TGF-β CLS 7.0 ± 3.6 6.4 ± 3.8 0.514 TGF-β SILI 3.0 ± 0.8 3.0 ± 0.9 0.471 Foxp3 LI 6.2 ± 4.1 6.8 ± 3.9 0.716
46
表9
腫瘤分期期數(Stage)與 IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、
標記分數之相關性
S1 + S2
(n= 27) (Mean ± SD)
S3 + S4
(n= 44) p-Value
IL-1β CLI 2.2 ± 1.1 2.8 ± 1.2 0.056
IL-1β IS 1.8 ± 0.8 2.1 ± 0.9 0.130
IL-1β CLS 4.3 ± 3.2 6.4 ± 4.1 0.030*
IL-1β SILI 2.8 ± 1.4 2.8 ± 1.2 0.987
IL-6 CLI 2.7 ± 1.2 3.0 ± 1.2 0.331
IL-6 IS 1.8 ± 0.8 1.9 ± 0.7 0.349
IL-6 CLS 5.4 ± 4.0 6.3 ± 3.9 0.316
IL-6 SILI 2.7 ± 1.0 2.6 ± 1.1 0.514 TGF-β CLI 3.3 ± 0.8 3.1 ± 1.0 0.368
TGF-β IS 2.0 ± 0.8 2.0 ± 0.8 0.855
TGF-β CLS 7.1 ± 3.7 6.7 ± 3.7 0.649 TGF-β SILI 2.8 ± 0.9 3.0 ± 1.0 0.507 Foxp3 LI 7.6 ± 4.2 5.5 ± 3.7 0.028*
47
表10
腫瘤細胞分化程度與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標 記分數之相關性
Well differentiation
(n= 57) (Mean ± SD)
Moderate differentiation
(n= 14)
p-Value
IL-1β CLI 2.6 ± 1.2 2.4 ± 1.2 0.622
IL-1β IS 1.9 ± 0.8 2.2 ± 0.9 0.236
IL-1β CLS 5.6 ± 4.0 5.9 ± 3.9 0.798 IL-1β SILI 2.8 ± 1.3 2.6 ± 1.3 0.496
IL-6 CLI 3.0 ± 1.2 2.6 ± 1.3 0.269
IL-6 IS 1.9 ± 0.8 1.8 ± 0.7 0.610
IL-6 CLS 6.2 ± 4.0 4.9 ± 3.4 0.300
IL-6 SILI 2.7 ± 1.1 2.6 ± 0.9 0.776 TGF-β CLI 3.3 ± 0.9 2.5 ± 0.9 0.001*
TGF-β IS 2.0 ± 0.8 1.9 ± 0.9 0.399
TGF-β CLS 7.3 ± 3.7 5.0 ± 3.2 0.065 TGF-β SILI 2.9 ± 0.9 2.7 ± 0.8 0.421
Foxp3 LI 6.4 ± 4.0 6.1 ± 4.1 0.928
48
表11
淋巴管或血管侵犯與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標 記分數之相關性
Without LVP
(n= 53) (Mean ± SD)
With LVP
(n= 18) p-Value
IL-1β CLI 2.5 ± 1.2 2.9 ± 1.0 0.190
IL-1β IS 2.0 ± 0.8 1.8 ± 0.9 0.390
IL-1β CLS 5.6 ± 4.1 5.7 ± 3.7 0.810 IL-1β SILI 2.7 ± 1.4 3.0 ± 0.9 0.498
IL-6 CLI 2.8 ± 1.2 3.1 ± 1.3 0.536
IL-6 IS 1.9 ± 0.8 1.9 ± 0.8 0.977
IL-6 CLS 5.8 ± 3.8 6.4 ± 4.3 0.692
IL-6 SILI 2.6 ± 1.1 2.7 ± 1.0 0.924 TGF-β CLI 3.2 ± 0.9 3.0 ± 1.0 0.353
TGF-β IS 2.0 ± 0.8 1.9 ± 0.9 0.785
TGF-β CLS 6.9 ± 3.6 6.5 ± 3.9 0.703 TGF-β SILI 3.0 ± 0.9 2.6 ± 1.0 0.196
Foxp3 LI 6.0 ± 3.9 7.3 ± 4.1 0.153
LVP= lymphovascular permeation
49
表12
轉移淋巴結之膜外擴散與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、
標記分數之相關性
Without ECS
(n= 59) (Mean ± SD)
With ECS
(n= 12) p-Value
IL-1β CLI 2.5 ± 1.2 2.8 ± 1.1 0.563
IL-1β IS 1.9 ± 0.8 2.3 ± 0.9 0.214
IL-1β CLS 5.4 ± 3.9 6.8 ± 4.2 0.261 IL-1β SILI 2.8 ± 1.3 2.8 ± 1.1 0.766
IL-6 CLI 2.8 ± 1.2 3.3 ± 1.2 0.129
IL-6 IS 1.8 ± 0.7 2.2 ± 0.8 0.179
IL-6 CLS 5.6 ± 3.8 7.8 ± 4.4 0.096
IL-6 SILI 2.6 ± 1.1 2.9 ± 1.1 0.325 TGF-β CLI 3.2 ± 0.9 3.0 ± 1.2 0.709
TGF-β IS 2.1 ± 0.8 1.8 ± 1.0 0.290
TGF-β CLS 7.0 ± 3.6 6.2 ± 4.3 0.451 TGF-β SILI 3.0 ± 0.9 2.7 ± 1.1 0.561
Foxp3 LI 6.2 ± 3.9 6.8 ± 4.5 0.695
ECS= extracapsular spreading
50
表13
腫瘤復發與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數之 相關性
Without recurrence
(n= 52) (Mean ± SD)
With recurrence
(n= 19) p-Value
IL-1β CLI 2.6 ± 1.2 2.5 ± 1.2 0.841
IL-1β IS 1.9 ± 0.9 2.1 ± 0.7 0.438
IL-1β CLS 5.6 ± 4.1 5.6 ± 3.6 0.870 IL-1β SILI 2.8 ± 1.3 2.6 ± 1.2 0.381
IL-6 CLI 2.9 ± 1.2 2.7 ± 1.3 0.498
IL-6 IS 1.9 ± 0.8 1.9 ± 0.7 0.934
IL-6 CLS 6.1 ± 4.0 5.6 ± 3.8 0.692
IL-6 SILI 2.7 ± 1.0 2.4 ± 1.2 0.347 TGF-β CLI 3.3 ± 0.9 3.0 ± 1.1 0.319
TGF-β IS 2.0 ± 0.8 2.1 ± 0.8 0.836
TGF-β CLS 7.0 ± 3.6 6.5 ± 4.0 0.732 TGF-β SILI 2.9 ± 1.0 3.0 ± 0.9 0.723
Foxp3 LI 6.5 ± 4.1 5.9 ± 3.6 0.709
51
表14
酒精攝取與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數之 相關性
Without alcohol
consumption (n=10) (Mean ± SD)
With alcohol consumption
(n=61)
p-Value
IL-1β CLI 2.8 ± 1.0 2.5 ± 1.2 0.517
IL-1β IS 2.0 ± 0.7 2.0 ± 0.9 0.930
IL-1β CLS 5.6 ± 2.7 5.6 ± 4.1 0.732 IL-1β SILI 3.0 ± 0.9 2.7 ± 1.3 0.729
IL-6 CLI 2.5 ± 1.2 3.0 ± 1.2 0.274
IL-6 IS 1.7 ± 0.7 1.9 ± 0.8 0.426
IL-6 CLS 4.7 ± 3.6 6.2 ± 4.0 0.286
IL-6 SILI 2.0 ± 1.1 2.7 ± 1.0 0.047*
TGF-β CLI 3.1 ± 0.7 3.2 ± 1.0 0.503
TGF-β IS 2.3 ± 0.8 2.0 ± 0.8 0.233
TGF-β CLS 7.3 ± 3.2 6.7 ± 3.8 0.482 TGF-β SILI 3.0 ± 0.9 2.9 ± 0.9 0.728
Foxp3 LI 7.1 ± 2.6 6.2 ± 4.2 0.176
52
表15
嚼食檳榔與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數之 相關性
Without betel quid chewing
(n=7) (Mean ± SD)
With betel quid chewing
(n=64)
p-Value
IL-1β CLI 2.1 ± 1.1 2.6 ± 1.2 0.302
IL-1β IS 1.6 ± 0.8 2.0 ± 0.8 0.172
IL-1β CLS 3.3 ± 2.3 5.9 ± 4.0 0.126 IL-1β SILI 2.6 ± 1.4 2.8 ± 1.3 0.628
IL-6 CLI 2.7 ± 1.1 2.9 ± 1.3 0.575
IL-6 IS 1.4 ± 0.5 1.9 ± 0.8 0.099
IL-6 CLS 4.0 ± 2.4 6.2 ± 4.0 0.199
IL-6 SILI 2.3 ± 1.0 2.7 ± 1.1 0.333 TGF-β CLI 3.1 ± 0.7 3.2 ± 1.0 0.646
TGF-β IS 2.3 ± 0.8 2.0 ± 0.8 0.363
TGF-β CLS 7.3 ± 3.1 6.8 ± 3.8 0.605 TGF-β SILI 2.6 ± 1.1 2.9 ± 0.9 0.372 Foxp3 LI 9.1 ± 3.2 6.0 ± 4.0 0.021*
53
表16
抽菸與IL-1β、IL-6、TGF-β 與 Foxp 各項陽性染色標記指數、強度、標記分數之相關 性
Without smoking
(n=8) (Mean ± SD)
With smokine
(n=63) p-Value
IL-1β CLI 1.8 ± 1.0 2.7 ± 1.2 0.037*
IL-1β IS 1.5 ± 0.8 2.0 ± 0.8 0.083
IL-1β CLS 2.8 ± 2.4 6.0 ± 4.0 0.023*
IL-1β SILI 2.5 ± 1.5 2.8 ± 1.3 0.588
IL-6 CLI 2.6 ± 1.1 2.9 ± 1.3 0.422
IL-6 IS 1.5 ± 0.5 1.9 ± 0.8 0.139
IL-6 CLS 4.3 ± 2.8 6.2 ± 4.0 0.244
IL-6 SILI 2.4 ± 0.9 2.7 ± 1.1 0.429 TGF-β CLI 2.9 ± 0.6 3.2 ± 1.0 0.123
TGF-β IS 2.1 ± 0.6 2.0 ± 0.8 0.721
TGF-β CLS 6.1 ± 2.4 6.9 ± 3.8 0.713 TGF-β SILI 2.8 ± 1.0 2.9 ± 0.9 0.716
Foxp3 LI 8.3 ± 3.9 6.1 ± 4.0 0.091
54
圖1
IL-1β 於 OSCC 組織切片中的表現
(A) IL-1β 表現少於 10%的腫瘤細胞，且呈現輕度染色，主要表現於腫瘤巢之基底細胞 (B) IL-1β 表現於 10%-50%之腫瘤細胞，且呈現中度染色
(C) IL-1β 表現於 50%-80%之腫瘤細胞，且呈現中度染色 (D) IL-1β 表現於 80%-100%之腫瘤細胞，且呈現重度染色 (A、B、C、D original magnification × 100)
A B
C D
55
圖2
IL-6 於 OSCC 組織切片中的表現
(A) IL-6 表現少於 10%的腫瘤細胞，且呈現輕度染色，主要表現於腫瘤巢之基底細胞 (B) IL-6 表現於 10%-50%之腫瘤細胞，且呈現輕度至中度染色
(C) IL-6 表現於 50%-80%之腫瘤細胞，且呈現中度至重度染色 (D) IL-6 表現於 80%-100%之腫瘤細胞，且呈現重度染色 (A、B、C、D original magnification × 100)
A B
C D
56
圖3
TGF-β 於 OSCC 組織切片中的表現
(A) TGF-β 表現少於 10%的腫瘤細胞，且呈現輕度染色，主要表現於腫瘤巢之基底上 分化較完整之細胞
(B) TGF-β 表現於 10%-50%之腫瘤細胞，且呈現輕度至中度染色 (C) TGF-β 表現於 50%-80%之腫瘤細胞，且呈現中度至重度染色 (D) TGF-β 表現於 80%-100%之腫瘤細胞，且呈現重度染色 (A、B、C、D original magnification × 100)
A B
C D
57
圖4
Foxp3 於 OSCC 組織切片中的表現
(A) Foxp3 表現於約 2%的腫瘤浸潤淋巴球，且皆分布在靠近腫瘤的部位 (B) Foxp3 表現於約 5%的腫瘤浸潤淋巴球
(C) Foxp3 表現於約 10%的腫瘤浸潤淋巴球 (D) Foxp3 表現於約 15%的腫瘤浸潤淋巴球 (A、B、C、D original magnification × 500)
A B
C D
58
圖5
Kaplan-Meier 生存曲線與 IL-1β 癌細胞標記指數之關係 (Log-Rank p= 0.392)。
(n=34) (n=37)
59
圖6
Kaplan-Meier 生存曲線與 IL-1β 基質與浸潤之免疫細胞標記指數之關係(Log-Rank p=
0.493)。
(n=27) (n=44)
60
圖7
Kaplan-Meier 生存曲線與 IL-6 癌細胞標記指數之關係 (Log-Rank p= 0.594)。
(n=28) (n=43)
61
圖8
Kaplan-Meier 生存曲線與 IL-6 基質與浸潤之免疫細胞標記指數之關係(Log-Rank p=
0.626)。
(n=32) (n=39)
62
圖9
Kaplan-Meier 生存曲線與 TGF-β 癌細胞標記指數之關係 ，TGF-β 表現量大於 50%的 存活率較高，且有統計上的顯著差異(Log-Rank p= 0.024*)。
(n=13) (n=58)
63
圖10
Kaplan-Meier 生存曲線與 TGF-β 基質與浸潤之免疫細胞標記指數之關係(Log-Rank p=
0.166)。
(n=25) (n=46)
64
圖11
Kaplan-Meier 生存曲線與 Foxp3 之標記指數之關係(Log-Rank p= 0.840)。
(n=49) (n=22)
65
參考文獻
Abe M, Kondo S, Hirano S, Ambo Y, Tanaka E, Morikawa T, Okushiba S, and Katoh H.
2003. Long-term survival after radical resection of advanced pancreatic cancer: a case report with special reference to CD8+ T-cell infiltration. Int J Gastrointest Cancer 33(2-3):107-110.
Achen MG, McColl BK, and Stacker SA. 2005. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7(2):121-127.
Achur RN, Freeman WM, and Vrana KE. 2010. Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J Neuroimmune Pharmacol 5(1):83-91.
Ahn JM, Huang CC, and Cho HT. 1993. Localization of interleukin-1 in human squamous carcinomas of the head and neck. Laryngoscope 103(5):529-532.
Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, and Piris MA. 2005. Outcome in Hodgkin's lymphoma can be
predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11(4):1467-1473.
Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, and Romagnani S. 2002. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 196(3):379-387.
Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, and Voronov E. 2006a. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387-408.
Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L et al. . 2006b. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 42(6):751-759.
Apte RN, and Voronov E. 2002. Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 12(4):277-290.
Apte RN, and Voronov E. 2008. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 222:222-241.
Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH et al. . 2006. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12(2):465-472.
Balkwill F, Charles KA, and Mantovani A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211-217.
Beauchemin V, Villeneuve L, Rodriguez-Cimadevilla JC, Rajotte D, Kenney JS, Clark SC, and Hoang T. 1991. Interleukin-6 production by the blast cells of acute myeloblastic leukemia: regulation by endogenous interleukin-1 and biological implications. J Cell Physiol 148(3):353-361.
Becker C, Fantini MC, and Neurath MF. 2006. TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 17(1-2):97-106.
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S et al. . 2004. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21(4):491-501.
66
Benitez-Bribiesca L, Wong A, Utrera D, and Castellanos E. 2001. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 49(8):1061-1062.
Berger FG. 2004. The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat 88(3):281-285.
Bergers G, and Benjamin LE. 2003. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401-410.
Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P, Chen W, Flanders KC, Gutkind JS, Wakefield LM et al. . 2009. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res 69(14):5918-5926.
Bissell MJ, and Radisky D. 2001. Putting tumours in context. Nat Rev Cancer 1(1):46-54.
Boccia S, Hashibe M, Galli P, De Feo E, Asakage T, Hashimoto T, Hiraki A, Katoh T, Nomura T, Yokoyama A et al. . 2009. Aldehyde dehydrogenase 2 and head and neck cancer: a meta-analysis implementing a Mendelian randomization approach.
Cancer Epidemiol Biomarkers Prev 18(1):248-254.
Boffetta P. 2008. Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl(218):45-54.
Bommert K, Bargou RC, and Stuhmer T. 2006. Signalling and survival pathways in multiple myeloma. Eur J Cancer 42(11):1574-1580.
Bose A, Chakraborty T, Chakraborty K, Pal S, and Baral R. 2008. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 8:10.
Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, and Zanovello P. 2000. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96(12):3838-3846.
Brunnemann KD, Prokopczyk B, Djordjevic MV, and Hoffmann D. 1996. Formation and analysis of tobacco-specific N-nitrosamines. Crit Rev Toxicol 26(2):121-137.
Carpenter JM, Syms MJ, and Sniezek JC. 2005. Oral carcinoma associated with betel nut chewing in the Pacific: an impending crisis? Pac Health Dialog 12(1):158-162.
Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, and Kaufman HL. 2006. Characterization of
CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24(7):1169-1177.
Chang MC, Chiang CP, Lin CL, Lee JJ, Hahn LJ, and Jeng JH. 2005. Cell-mediated immunity and head and neck cancer: with special emphasis on betel quid chewing habit. Oral Oncol 41(8):757-775.
Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, and Anderson KC. 1996. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87(3):1104-1112.
Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, and Khazaie K.
2005a. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through
67
TGF-beta signals in vivo. Proc Natl Acad Sci U S A 102(2):419-424.
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, and Wahl SM. 2003.
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med
198(12):1875-1886.
Chen W, Perruche S, and Li J. 2007. CD4+CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem 14(21):2245-2249.
Chen W, and Wahl SM. 2003. TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 14(2):85-89.
Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, and Cheng AJ.
2008. Head and neck cancer in the betel quid chewing area: recent advances in
2008. Head and neck cancer in the betel quid chewing area: recent advances in